Digital Content 
NEWS #PharmaBuzz
13 Aug 2025
// PRESS RELEASE
https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-second-quarter-2025-financial-results-and#:~:text=Phase%203%20trial%20in%20OCD%20with%20troriluzole%20was%20completed%20with%20no%20efficacy%20signal%20detected.%20The%20OCD%20development%20program%20is%20being%20ended%20to%20allow%20resources%20to%20be%20applied%20to%20other%20development%20programs.%20Study%20results%20will%20be%20presented%20at%20an%20upcoming%20academic%20meeting.
14 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-extends-pdufa-date-of-biohavens-troriluzole-nda-for-rare-disease-spinocerebellar-ataxia-302455920.html
11 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biohaven-announces-fda-acceptance-and-priority-review-of-troriluzole-new-drug-application-for-the-treatment-of-spinocerebellar-ataxia-302373056.html
16 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biohaven-reports-positive-phase-1-degrader-data-achieving-deep-targeted-igg-reductions-in-the-lowest-subcutaneous-dose-tested-announces-nda-submission-for-troriluzole-in-sca-and-provides-other-key-program-updates-302332472.html
24 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biohaven-achieves-positive-topline-results-in-pivotal-study-of-troriluzole-in-spinocerebellar-ataxia-sca-302255056.html
20 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebellar-ataxia-302254638.html
Share 